MYPATH MELANOMA
MyPath Melanoma is the CLIA-certified laboratory in Salt Lake City that offers the myPath Melanoma test. MyPath Melanoma has been used by almost 40,000 patients to guide treatment decisions and has been ordered by approximately 20% of dermatopathologists in the country.
MYPATH MELANOMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.mypathmelanoma.com
Status:
Active
Contact:
(800) 231-4442
Email Addresses:
[email protected]
Technology used in webpage:
Amazon GoDaddy DNS Person Schema Gravatar Profiles AWS Global Accelerator
Similar Organizations
HealthWright Technologies
HealthWright Technologies is a healthcare service provider & pharmaceutical firm that provides healthcare technology & patient services.
Rochester Drug Cooperative
Rochester Drug Cooperative is a pharmaceuticals company that offers wholesale drugs.
Official Site Inspections
http://www.mypathmelanoma.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MyPath Melanoma"
MyPath Melanoma - Castle Biosciences
MyPath Melanoma gene expression profile (GEP) test is designed to provide objective information to aid in the diagnosis and to inform management decisions for patients with ambiguous melanocytic lesions.See details»
MyPath Melanoma Order Process & Results - Castle …
MyPath Melanoma is intended to aid in the characterization of primary cutaneous melanocytic lesions with uncertain malignant potential. Test results should be interpreted in the context of other clinical, laboratory and histological …See details»
myPath® Melanoma – Gene Analysis
Understanding the myPath ® Melanoma Results. The myPath ® Melanoma test result is a single numerical score that classifies melanocytic lesions as likely benign, likely malignant, or …See details»
MyPath Melanoma How It Works - Castle Biosciences
Using qRT-PCR technology, MyPath Melanoma objectively distinguishes melanoma from benign nevi with greater than 90% accuracy in three independent clinical validation studies.See details»
Exploring the MyPath Melanoma Test for Guiding Management …
May 1, 2024 · In this installment of Discourses in Dermatology, Aaron Farberg, MD, gives an in-depth overview of the MyPath Melanoma test, a gene expression profile (GEP) test designed …See details»
mymelanomadiagnosis
The MyPath Melanoma or DecisionDx DiffDx-Melanoma test may be ordered by the dermatopathologist or dermatologist to gather additional information. This testing analyzes the …See details»
Impact Melanoma - IMPACT Melanoma
IMPACT Melanoma is the nation’s leading non-profit dedicated to significantly reducing the incidence of melanoma in the United States and saving lives. What’s in a name? We are passionate about increasing awareness of skin cancer …See details»
Use of new molecular tests for melanoma by pigmented-lesion …
Aug 13, 2019 · The myPath Melanoma test (Myriad, Salt Lake City, UT) is based on the expression of 23 genes from formalin-fixed material that may serve as an adjunct to histologic …See details»
MyPath Melanoma Resources | Castle Biosciences
Listen to multiple clinicians discuss how gene expression profile testing can provide guidance for difficult-to-diagnose lesions and improve patient management. Increase diagnostic clarity for ambiguous melanocytic lesions …See details»
Canadian Melanoma Organizations - Canadian Cancer Survivor …
Promote awareness of melanoma and the importance of prevention and early self-detection. Provide funding and support for education and research into the causes, controls, and cure of …See details»
MyMelanoma Institute Collaborative Research Project
Based at the Universities of Leeds and Oxford, MyMelanoma is a one-of-a-kind and collaborative research project working with melanoma sufferers to facilitate the most ambitious melanoma …See details»
New Study Demonstrates the Ability of myPath® Melanoma to …
Jun 25, 2020 · Myriad myPath Melanoma is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma …See details»
Technological advances for the detection of melanoma
These have been developed as adjunct tools for melanoma management and include the Pigmented Lesion Assay, myPath Melanoma, and DecisionDx-Melanoma tests, and genetic …See details»
How MyPath Melanoma Resolves Uncertainty in Diagnosing Skin …
Watch to learn how MyPath Melanoma improves diagnostic confidence and clinical decision-making in dermatology. Board-certified dermatologist and dermatopathologist Dr. Neil …See details»
MyPath Melanoma for Dermatopathologists - Castle Biosciences
Learn how MyPath Melanoma provided clarity to a dermatopathologist who was faced with diagnostic uncertainty. Melanoma or Severely Inflamed Spitz Nevus? Ready to incorporate …See details»
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III …
Jun 2, 2024 · In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by …See details»
How MyPath Melanoma Brings Clarity to Patients: Dr. Shannon …
By providing clarity and confidence in a diagnosis, MyPath Melanoma empowers both patients and physicians to move forward with effective treatment plans. Watch to learn how this …See details»
MyPath Melanoma Practice Integration | Castle Biosciences
MyPath Melanoma is a clinically validated, accurate and objective GEP test intended to resolve diagnostic ambiguity for melanocytic lesions of uncertain malignant potential. The clinical utility …See details»
When to Use MyPath Melanoma: Dr. Neil Fernandes on Managing …
Dr. Neil Fernandes, board certified dermatologist and dermatopathologist, explains the scenarios in which he relies on MyPath Melanoma for challenging pigmented lesions. With a dual role of...See details»
MyPath Melanoma Scientific Evidence | Castle Biosciences
The MyPath Melanoma test objectively distinguishes melanomas from benign nevi with greater than 90 percent accuracy in three independent clinical validations.See details»